Glenmark Pharmaceuticals Ltd Share Price (GLENMARK)
Check the latest share price of Glenmark Pharmaceuticals Ltd, along with the price target, peer comparison, quarterly results, recent news, expert analysis, shareholding pattern, and other key fundamentals to make informed investment decisions.
as on 04:01PM, 13 Jun 2025
NSE
Glenmark Pharmaceuticals Ltd Stock Performance
Get live Glenmark Pharmaceuticals Ltd share price, day's high and low, historical returns, and market stats.
Day's Low
Day's High
₹1,605Day's Price Range₹1,67452 Week's Low
52 Week's High
₹1,182.552-Week Price Range₹1,830.95
| Returns % | |
| 1 Month Return | + 15.73 % |
| 3 Month Return | + 16.81 % |
| 1 Year Return | + 34.98 % |
| 3 Year Return | + 337.15 % |
| 5 Year Return | + 322.39 % |
| Market Stats | |
| Previous Close | ₹1,639.60 |
| Open | ₹1,605.00 |
| Volume | 9.38L |
| Upper Circuit | ₹1,803.50 |
| Lower Circuit | ₹1,475.70 |
Glenmark Pharmaceuticals Ltd Fundamentals & Key Indicators
Check Glenmark Pharmaceuticals Ltd market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹47,124.71 Cr
Return on Equity (ROE)
6.98
PE Ratio (TTM)
45.01
Return on capital employed (ROCE)
9.75
Industry PE ratio
57.39
Beta (LTM)
0.85
P/B Ratio
1.18
Dividend Yield
0.26
PEG Ratio
0.5
Quarterly Earnings Growth YOY
-100.36
EPS (TTM)
-50.8
Sector
Pharmaceuticals
Book Value
278.11
Technical Analysis
Bullish
View Technical Analysis
How to invest in Glenmark Pharmaceuticals Ltd?
Investing in Glenmark Pharmaceuticals Ltd is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Glenmark Pharmaceuticals Ltd or GLENMARK on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Glenmark Pharmaceuticals Ltd or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Glenmark Pharmaceuticals Ltd with just a few clicks!
Glenmark Pharmaceuticals Ltd Stock's Interest Amongst Investors
Glenmark Pharmaceuticals Ltd Valuation
Track how Glenmark Pharmaceuticals Ltd P/E has moved over time to understand its valuation trends.
Glenmark Pharmaceuticals Ltd in the last 5 years
Lowest (-275.05x)
December 28, 2023
Today (45.01x)
June 13, 2025
Industry (57.39x)
June 13, 2025
Highest (95.94x)
September 14, 2023
Today’s Price to Earnings Ratio: 45.01x
Glenmark Pharmaceuticals Ltd Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Glenmark Pharmaceuticals Ltd.
based on 12 analysts
75.00%
Buy
16.67%
Hold
8.33%
Sell
75% of analysts recommend a 'BUY' rating for Glenmark Pharmaceuticals Ltd. Average target price of ₹1678.42
Source: S&P Global Market Intelligence
Glenmark Pharmaceuticals Ltd Share Price Target
Get share price movements and forecasts by analysts on Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Ltd price forecast by 12 analysts
Upside of0.51%
High
₹2011
Target
₹1678.42
Low
₹1300
Glenmark Pharmaceuticals Ltd target price ₹1678.42, a slight upside of 0.51% compared to current price of ₹1669.9. According to 12 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Glenmark Pharmaceuticals Ltd revenue growth forecast
Expected growth rate Q1, FY2027:39.85%
Forecast
Actual
Including amortisation and stock based compensations
Glenmark Pharmaceuticals Ltd EPS growth forecast
EPS estimate Q1, FY2027:
Forecast
Actual
Source: S&P Global Market Intelligence
Glenmark Pharmaceuticals Ltd Financial Results
Get the annual and quarterly financial summary of Glenmark Pharmaceuticals Ltd, including revenue, profit, loss and more.
Indices Featuring Glenmark Pharmaceuticals Ltd Stock
Check stock indices that include Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Ltd Earnings and Dividends
View detailed summary of the earnings and dividend history of Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Ltd Earnings Results
Glenmark Pharmaceuticals Ltd’s net profit jumped 100.38% since last year same period to ₹4.65Cr in the Q4 2024-2025. On a quarterly growth basis, Glenmark Pharmaceuticals Ltd has generated -98.66% fall in its net profits since last 3-months.
Read More about Earnings ResultsGlenmark Pharmaceuticals Ltd Dividends May,2024
In the quarter ending March 2024, Glenmark Pharmaceuticals Ltd has declared dividend of ₹2.50 - translating a dividend yield of 0.15%.
Read More about Dividends
Glenmark Pharmaceuticals Ltd Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Glenmark Pharmaceuticals Ltd.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 46.65% | 0.00 | |
| Foreign Institutions | 23.16% | 0.00 | |
| Mutual Funds | 12.86% | 0.00 | |
| Retail Investors | 15.56% | 0.00 | |
| Others | 1.78% | 0.00 |
Glenmark Pharmaceuticals Ltd vs Peers
Compare market cap, revenue, PE, and other key metrics of Glenmark Pharmaceuticals Ltd with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| BUY | 47,124.71 | 64.48% | 0.52 | -1,434 | 11,813 | |
| BUY | 38,428.87 | 101.79% | 0.52 | 300 | 1,051 | |
| BUY | 17,430.61 | 17.42% | 0.57 | 72 | 6,702 | |
| NA | 5,383.81 | 2.8% | 0.79 | -388 | 75 | |
| BUY | 14,436.59 | 43.15% | 0.68 | 244 | 1,515 |
Glenmark Pharmaceuticals Ltd News & Key Events
Latest news and events in one place to help you make informed investing decisions in Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Continues Upward Trend - 11 Jun, 2025
Glenmark Pharmaceuticals Ltd rose 0.98% on June 11, 2025, marking its fifth consecutive session of gains. The stock is up 35.62% over the past year, outperforming both the NIFTY and Nifty Pharma indices. It has also increased 18.07% in the last month, with a current price of Rs 1631.4.Glenmark Launches Brukinsa for Blood Cancer Treatment - 09 Jun, 2025
Glenmark Pharmaceuticals has launched zanubrutinib (Brukinsa) in India, the first BTK inhibitor approved for five B-cell malignancies, following DCGI approval. This innovative therapy addresses critical treatment needs in blood cancer care.Glenmark Pharma Exhibits Bullish Breakout Signals - 06 Jun, 2025
Glenmark Pharmaceuticals has confirmed a bullish triangle breakout, with strong momentum indicated by RSI above 70. Targets are set at ₹1,660-1,690, with support at ₹1,528.Glenmark Pharma Breaks Out of Corrective Phase - 05 Jun, 2025
Glenmark Pharmaceuticals has ended an eight-month corrective phase with a breakout above a declining trendline and increased trading volumes. The stock has reclaimed key moving averages, suggesting a positive outlook and potential for long positions.Analyst Recommends Buy on Glenmark Pharmaceuticals - 04 Jun, 2025
An analyst recommends buying Glenmark Pharmaceuticals at Rs 1,512, with a stop-loss at Rs 1,470 and a target price of Rs 1,600. The company specializes in generic drugs and active pharmaceutical ingredients.Glenmark's ISB 2001 Drug Shows Promising Trial Results - 02 Jun, 2025
Glenmark Pharmaceuticals' investigational drug ISB 2001 demonstrated a 79% overall response rate in relapsed or refractory multiple myeloma patients during Phase 1 trials. The drug's promising results and favorable safety profile have garnered FDA Fast Track designation, indicating its potential to address significant medical needs in this patient population.Analyst Recommends Buy on Glenmark Pharmaceuticals - 30 May, 2025
Analyst Palviya recommends buying Glenmark Pharma shares at Rs 1,406, with a stop loss at Rs 1,387 and a target price of Rs 1,445. Glenmark is a leading Indian pharmaceutical company with a global presence.Glenmark Faces Target Price Cut Amid Declining Income - 29 May, 2025
ICICI Securities has maintained a Reduce call on Glenmark Pharmaceuticals, raising the target price to Rs 1,300. The company reported a decline in total income and net profit for the latest quarter.Glenmark Pharma Targets Licensing Deal and Price Update - 28 May, 2025
Glenmark Pharmaceuticals is in talks for a licensing deal on ISB 2001, a cancer drug candidate. Motilal Oswal sets a target price of Rs 1690 amid mixed quarterly results.HSBC Maintains Buy Rating on Glenmark Pharma - 27 May, 2025
HSBC has reiterated a buy rating on Glenmark Pharmaceuticals, targeting ₹1,720, citing potential growth in India and US markets and a key outlicensing deal for ISB 2001 as a catalyst for re-rating.Glenmark Shares Decline After Q4 Earnings Miss - 26 May, 2025
Glenmark Pharmaceuticals reported a 3.53% drop in shares following Q4 results that fell short of expectations, despite a 6.3% revenue increase. Nomura maintained a 'Neutral' rating with a target price of ₹1,500, citing concerns over financial performance and increased debt.Glenmark Reports Strong Q4FY25 Financial Performance - 25 May, 2025
Glenmark Pharmaceuticals reported a 6.3% increase in consolidated revenue to ₹3,256 crore for Q4FY25. EBITDA rose 11.2% to ₹561 crore, with an improved margin of 17.2%. Adjusted PAT was ₹347 crore, reflecting a margin of 10.6%.Glenmark Reports Profit and Launches New Subsidiary - 24 May, 2025
Glenmark Pharmaceuticals reported a consolidated net profit of Rs 4.65 crore for the March 2025 quarter, recovering from a loss. Additionally, it incorporated Glenmark Consumer Care as a wholly-owned subsidiary to expand its product offerings.Glenmark Reports Strong Q4 Results and Dividend - 23 May, 2025
Glenmark Pharmaceuticals announced an 11% increase in Q4 net profit, driven by strong European sales. The company declared a Rs 2.5 dividend per share, pending AGM approval, with total payouts reaching Rs 70.5 crore.
Insights on Glenmark Pharmaceuticals Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 12.12% to 12.86% in Mar 2025 quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, GLENMARK has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Price Rise
In the last 7 days, GLENMARK stock has moved up by 4.4%
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 46.65% of holdings in Mar 2025 quarter
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 45.3% return, outperforming this stock by 10.3%
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 23.51% to 23.16% in Mar 2025 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 15.96% to 15.56% in Mar 2025 quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 3 quarters, 354.21 Cr → 4.65 Cr (in ₹), with an average decrease of 50.2% per quarter
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 3 quarters, 3.47K Cr → 3.26K Cr (in ₹), with an average decrease of 3.0% per quarter
About Glenmark Pharmaceuticals Ltd
Revenue: ₹3,220.13Cr as on March 2025 (Q4 FY25)
Net Profit: ₹4.38Cr as on March 2025 (Q4 FY25)
Listing date: 07 Feb, 2000
Chairperson Name: Glenn Saldanha
| Organisation | Glenmark Pharmaceuticals Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| CEO | Glenn Saldanha |
| E-voting on shares | Click here to vote |
Mutual Funds that own Glenmark Pharmaceuticals Ltd
Check out the Mutual Funds with significant holdings in Glenmark Pharmaceuticals Ltd.
FAQs
What is Glenmark Pharmaceuticals Ltd share price today?
Glenmark Pharmaceuticals Ltd share price today stands at ₹1669.9, Open: ₹1605, Previous Close: ₹1639.6, High: ₹1674, Low: ₹1605, 52 Week High: ₹1830.95, 52 Week Low: ₹1182.5.
What is today's traded volume of Glenmark Pharmaceuticals Ltd?
Today's traded volume of Glenmark Pharmaceuticals Ltd is 9.38L. Which means that 9.38L shares of Glenmark Pharmaceuticals Ltd were bought and sold on the stock market during today's trading session.
What is Glenmark Pharmaceuticals Ltd's market cap today?
Today's market capitalisation of Glenmark Pharmaceuticals Ltd is ₹47,124.71 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd’s 52 week high is ₹1830.95 and 52 week low is ₹1182.5. The current share price of Glenmark Pharmaceuticals Ltd is ₹1669.9, which is -8.80% down from its 52 week high and 41.22% up from its 52 week low.